• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.

作者信息

Bissell Brittany D, Mefford Breanne, Donaldson J Chris

出版信息

Ann Pharmacother. 2022 Apr;56(4):505-506. doi: 10.1177/10600280211036040. Epub 2021 Jul 30.

DOI:10.1177/10600280211036040
PMID:34330160
Abstract
摘要

相似文献

1
Comment: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.评论：对于因COVID-19低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率，且不会增加感染风险。
Ann Pharmacother. 2022 Apr;56(4):505-506. doi: 10.1177/10600280211036040. Epub 2021 Jul 30.
2
Reply: Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.回复：对于因 COVID-19 低氧性呼吸衰竭住院的患者，低剂量托珠单抗联合高剂量皮质类固醇可改善死亡率且不增加感染风险。
Ann Pharmacother. 2022 Apr;56(4):507-508. doi: 10.1177/10600280211036047. Epub 2021 Jul 30.
3
Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.COVID-19 低氧性呼吸衰竭住院患者使用低剂量托珠单抗联合大剂量皮质类固醇治疗可改善死亡率而不增加感染风险。
Ann Pharmacother. 2022 Mar;56(3):237-244. doi: 10.1177/10600280211028882. Epub 2021 Jun 28.
4
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.在重症 COVID-19 肺炎和中度炎症反应患者中，单独使用皮质类固醇或与托珠单抗联合使用阿那白滞素后的情况。一项回顾性队列研究：评论
Intern Emerg Med. 2021 Jun;16(4):1101-1103. doi: 10.1007/s11739-021-02663-6. Epub 2021 Feb 18.
5
Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.托珠单抗与皮质类固醇联合治疗重症SARS-CoV-2疾病
Med Intensiva (Engl Ed). 2022 May;46(5):285-287. doi: 10.1016/j.medine.2022.02.013. Epub 2022 Feb 24.
6
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.托珠单抗治疗后血栓炎症生物标志物的变化趋势比严重SARS-CoV2相关呼吸衰竭患者的评分更能预测治疗失败。
Eur J Intern Med. 2022 Sep;103:111-112. doi: 10.1016/j.ejim.2022.06.004. Epub 2022 Jun 6.
7
Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.托珠单抗并未降低 COVID-19 住院患者的低氧性呼吸衰竭或死亡风险。
Ann Intern Med. 2021 Feb;174(2):JC16. doi: 10.7326/ACPJ202102160-016. Epub 2021 Feb 2.
8
Early Combination of Tocilizumab and Corticosteroids: An Upgrade in Anti-inflammatory Therapy for Severe Coronavirus Disease (COVID).托珠单抗与皮质类固醇的早期联合应用：重症冠状病毒病（COVID）抗炎治疗的升级
Clin Infect Dis. 2021 May 4;72(9):1682-1683. doi: 10.1093/cid/ciaa910.
9
Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.托珠单抗治疗 SARS-CoV-2 相关严重呼吸衰竭患者预后不良的预测因素：一项多中心真实世界研究。
Int Immunopharmacol. 2022 Jun;107:108709. doi: 10.1016/j.intimp.2022.108709. Epub 2022 Mar 18.
10
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.在重度新型冠状病毒肺炎和中度炎症反应患者中，单用皮质类固醇或联合托珠单抗治疗后使用阿那白滞素：一项回顾性队列研究：回复
Intern Emerg Med. 2021 Jun;16(4):1105-1106. doi: 10.1007/s11739-021-02690-3. Epub 2021 Mar 10.